Fanshawe Thomas R, Halliwell William, Lindson Nicola, Aveyard Paul, Livingstone-Banks Jonathan, Hartmann-Boyce Jamie
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Cochrane Database Syst Rev. 2017 Nov 17;11(11):CD003289. doi: 10.1002/14651858.CD003289.pub6.
Most tobacco control programmes for adolescents are based around prevention of uptake, but teenage smoking is still common. It is unclear if interventions that are effective for adults can also help adolescents to quit. This is the update of a Cochrane Review first published in 2006.
To evaluate the effectiveness of strategies that help young people to stop smoking tobacco.
We searched the Cochrane Tobacco Addiction Group's Specialized Register in June 2017. This includes reports for trials identified in CENTRAL, MEDLINE, Embase and PsyclNFO.
We included individually and cluster-randomized controlled trials recruiting young people, aged under 20 years, who were regular tobacco smokers. We included any interventions for smoking cessation; these could include pharmacotherapy, psycho-social interventions and complex programmes targeting families, schools or communities. We excluded programmes primarily aimed at prevention of uptake. The primary outcome was smoking status after at least six months' follow-up among those who smoked at baseline.
Two review authors independently assessed the eligibility of candidate trials and extracted data. We evaluated included studies for risk of bias using standard Cochrane methodology and grouped them by intervention type and by the theoretical basis of the intervention. Where meta-analysis was appropriate, we estimated pooled risk ratios using a Mantel-Haenszel fixed-effect method, based on the quit rates at six months' follow-up.
Forty-one trials involving more than 13,000 young people met our inclusion criteria (26 individually randomized controlled trials and 15 cluster-randomized trials). We judged the majority of studies to be at high or unclear risk of bias in at least one domain. Interventions were varied, with the majority adopting forms of individual or group counselling, with or without additional self-help materials to form complex interventions. Eight studies used primarily computer or messaging interventions, and four small studies used pharmacological interventions (nicotine patch or gum, or bupropion). There was evidence of an intervention effect for group counselling (9 studies, risk ratio (RR) 1.35, 95% confidence interval (CI) 1.03 to 1.77), but not for individual counselling (7 studies, RR 1.07, 95% CI 0.83 to 1.39), mixed delivery methods (8 studies, RR 1.26, 95% CI 0.95 to 1.66) or the computer or messaging interventions (pooled RRs between 0.79 and 1.18, 9 studies in total). There was no clear evidence for the effectiveness of pharmacological interventions, although confidence intervals were wide (nicotine replacement therapy 3 studies, RR 1.11, 95% CI 0.48 to 2.58; bupropion 1 study RR 1.49, 95% CI 0.55 to 4.02). No subgroup precluded the possibility of a clinically important effect. Studies of pharmacotherapies reported some adverse events considered related to study treatment, though most were mild, whereas no adverse events were reported in studies of behavioural interventions. Our certainty in the findings for all comparisons is low or very low, mainly because of the clinical heterogeneity of the interventions, imprecision in the effect size estimates, and issues with risk of bias.
AUTHORS' CONCLUSIONS: There is limited evidence that either behavioural support or smoking cessation medication increases the proportion of young people that stop smoking in the long-term. Findings are most promising for group-based behavioural interventions, but evidence remains limited for all intervention types. There continues to be a need for well-designed, adequately powered, randomized controlled trials of interventions for this population of smokers.
大多数针对青少年的烟草控制项目都围绕着预防吸烟展开,但青少年吸烟现象仍然普遍。目前尚不清楚对成年人有效的干预措施是否也能帮助青少年戒烟。这是2006年首次发表的Cochrane系统评价的更新版。
评估有助于年轻人戒烟的策略的有效性。
我们于2017年6月检索了Cochrane烟草成瘾小组的专业注册库。这包括CENTRAL、MEDLINE、Embase和PsyclNFO中识别出的试验报告。
我们纳入了招募20岁以下经常吸烟的年轻人的个体和整群随机对照试验。我们纳入了任何戒烟干预措施;这些措施可以包括药物治疗、心理社会干预以及针对家庭、学校或社区的综合项目。我们排除了主要旨在预防开始吸烟行为的项目。主要结局是基线时吸烟的人在至少六个月随访后的吸烟状况。
两位综述作者独立评估候选试验的合格性并提取数据。我们使用标准的Cochrane方法评估纳入研究的偏倚风险,并根据干预类型和干预的理论基础对其进行分组。在适当的情况下,我们基于六个月随访时的戒烟率,采用Mantel-Haenszel固定效应方法估计合并风险比。
41项涉及超过13000名年轻人的试验符合我们的纳入标准(26项个体随机对照试验和15项整群随机试验)。我们判断大多数研究在至少一个领域存在高偏倚风险或偏倚风险不明确。干预措施多种多样,大多数采用个体或团体咨询的形式,有无额外的自助材料以形成综合干预措施。8项研究主要使用计算机或信息干预,4项小型研究使用药物干预(尼古丁贴片或口香糖,或安非他酮)。有证据表明团体咨询有干预效果(9项研究,风险比(RR)1.35,95%置信区间(CI)1.03至1.77),但个体咨询无效果(7项研究,RR 1.07,95%CI 0.83至1.39),混合交付方式也无效果(8项研究,RR 1.26,95%CI 0.95至1.66),计算机或信息干预同样无效果(合并RR在0.79至1.18之间,共9项研究)。虽然置信区间较宽,但没有明确证据表明药物干预有效(尼古丁替代疗法3项研究,RR 1.11,95%CI 0.48至2.58;安非他酮1项研究,RR 1.49,95%CI 0.55至4.02)。没有亚组排除具有临床重要效应的可能性。药物治疗研究报告了一些被认为与研究治疗相关的不良事件,不过大多数是轻微的,而行为干预研究中未报告不良事件。我们对所有比较结果的确定性都很低或非常低,主要原因是干预措施的临床异质性、效应大小估计的不精确性以及偏倚风险问题。
仅有有限的证据表明行为支持或戒烟药物能提高长期戒烟的年轻人比例。基于团体的行为干预的结果最有前景,但所有干预类型的证据仍然有限。对于这一吸烟人群的干预措施,仍然需要设计良好、样本量充足的随机对照试验。